Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    OpGen

    MCap

    USD7m

    Last close

    USD0.17

    ▲ 0.04 (30.77%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Context Therapeutics (NASDAQ: CNTX)

Currency in USD

Last close As at 25/01/2023

USD0.73

▲ 0.02 (2.82%)

Market capitalisation

USD12m

Context Therapeutics is a clinical-stage women’s oncology company. Lead candidate ONA-XR is a ‘full’ PRA being evaluated in three Phase II and one Phase Ib/II clinical trial in hormone-driven breast, endometrial and ovarian cancer. The other asset is a bi-specific monoclonal antibody, CLDN6xCD3.

According to the American Cancer Society, there were an estimated 284,200 breast cancer cases, 66,570 endometrial cancer cases and 21,410 ovarian cancer cases in the United States in 2021 (more than 70% of these are hormone-driven). Long-term survival rates remain low (c 30% for HR+/HER2- mBC) despite recent advances, highlighting the high unmet need in the metastatic space.

Latest Insights

View More

Healthcare

Context Therapeutics — Manufacturing agreement with Lonza for CTIM-76

Healthcare

Context Therapeutics — A catalyst-rich period ahead

Healthcare

Context Therapeutics — Initial data from the SMILE study encouraging

Healthcare

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Jennifer Minai-Azary

    CFO

  • Martin Lehr

    CEO

Balance Sheet

Forecast net cash (US$m)

34.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 15.4 (28.7) (67.5)
Relative 10.4 (32.6) (64.4)
52 week high/low US$2.7/US$0.6

Financials

Context Therapeutics has signed a manufacturing agreement with Lonza to develop CTIM-76 (active ingredient and final product form), its bispecific antibody clinical candidate for claudin 6 (CLDN6)-positive cancers. The collaboration marks a crucial step required to progress CTIM-76 towards the clinic. As a reminder, in December 2022, Context announced the selection of CTIM-76 as its CLDN6 clinical candidate (co-developed with partner Integral Molecular) and is currently undertaking investigative new drug (IND)-enabling studies with the goal of submitting the IND application in Q124.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 0.0 (2.6) (3.2) (928.15) N/A N/A
2021A 0.0 (10.5) (10.6) (373.72) N/A N/A
2022E 0.0 (18.1) (18.1) (113.20) N/A N/A
2023E 0.0 (27.4) (27.4) (171.71) N/A N/A

Research

View All

More from our Healthcare team

Healthcare

Healthcare Week 2023

Healthcare

Context Therapeutics: Delivering treatments in the female oncology space

Healthcare

Forging better lives: Seeking radical change for cancers

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free